ASLAN Pharmaceuticals’ A4 webinar series, Aspects of Atopic Dermatitis and ASLAN004
About The Event
This second webinar in ASLAN’s A4 webinar series “Dialogues with International Thought Leaders in Dermatology” will feature a presentation by Key Opinion Leader (KOL) April Armstrong MD MPH (University of Southern California), who will discuss the key factors affecting patient responses in atopic dermatitis (AD) clinical trials. Dr Armstrong has conducted over 150 clinical trials and has extensive medical expertise in inflammatory skin diseases, with a specialty in AD.
Following Dr Armstrong’s presentation, Karen Veverka PhD, Vice President Medical at ASLAN, will briefly review ASLAN Pharmaceuticals’ Phase 2b study design for ASLAN004, a novel, first-in-class monoclonal antibody. ASLAN004 targets the IL-13 receptor α1 subunit (IL-13Rα1), one of the components of the Type 2 receptor. By blocking the Type 2 receptor, ASLAN004 prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) – the key drivers of inflammation in AD. The unique mechanism of action has the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen.
A live question and answer session will follow the formal presentations.